基线Lp(a)较高时,PCSK9抑制剂带来更大的Lp(a)绝对降低,但百分比降低较小[12,13]。Watts等研究[14]证明,他汀类药物对Lp(a)水平或apo(a)动力学无影响;依洛尤单抗单药治疗降低apo(a)生成率,对apo(a)分解代谢率(FCR)无影响;而二者联合对apo(a...
Lipoprotein(a)AtherosclerosisPurpose It has been reported that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can significantly reduce lipoprotein(a) [Lp(a)], and the mechanism for Lp(a) reduction remains unclear. Recently an interesting clinical research with a small sample showed...
Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) LevelsLipoprotein (a) [Lp(a)] is a prevalent genetic risk factor for coronary artery disease [1] and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated significant Lp(a)-lowering effects [2, 3]....
Targeting PCSK9 inhibitors to those who will benefit most. Lancet Diabetes Endocrinol. 2022;10(5):301–3. Article CAS PubMed Google Scholar Boccara F, Caramelli B, Calmy A, Kumar P, López JAG, Bray S, et al. Long-term effects of evolocumab in participants with HIV and dyslipidemia:...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear. Hence, we employed Mendelian randomization (MR) analysis for
PCSK9抑制剂比他汀类药物的优势是,他汀类药物不会显著降低脂蛋白(a)[LP(a)]水平,这是CVD的一个独立危险因素,而PCSK9抑制剂则会降低。这是因为PCSK9参与LDL相关蛋白-1的降解,该蛋白分解LP(a),因此,抑制PCSK9会提高LDL相关蛋白-1的水平,从而增加LP(a)的分解。
Reiner Z. PCSK9 inhibitors e past, present and future. Expert Opin Drug Metab Toxicol 2015;11(10):1517e21. http: //dx.doi.org/10.1517/17425255.2015.1075506 [Epub 2015 Sep 2].Clin Chem REINER Z. PCSK9 inhibitors-past, present and future [J]. Expert Opin Drug Metab Toxicol, 2015, 11...
关键词 动脉粥样硬化，PCSK9抑制剂，脂蛋白a ，动脉壁炎症，内皮细胞功能，动脉斑块纤维帽的厚度和 稳定性 Prevention and Influence of PCSK9 Inhibitors in Atherosclerotic (AS) Diseases Xiuling Wang 1*, Qiang Geng 2, Qianqian Wu 2, Zhengzhong Wang 2# 1 Department of Medicine, Qingdao University, Qin...
Update on the use of 试者进入第二阶段,在这个阶段中,这些受试者被 PCSK9 inhibitors in adults: recommendations from an expert panel of 随机分配到接受依折麦布或Evolocumab治疗24周。 the National Lipid Association. J Clin Lipidol, 2017, 11: 880-890. [2] Robinson JG, Farnier M, Krempf M,...
的获批是基于三项3期注册临床试验(CREDIT-1、CREDIT-2和CREDIT-4)的研究结果:与安慰剂相比,托莱西单抗注射液可降低低密度脂蛋白胆固醇(LDL-C)水平约57%~65%,且可维持长期治疗疗效;此外,托莱西单抗注射液还可明显降低总胆固醇(TC)、非高密度脂蛋白胆固醇(Non-HDL-C)、载脂蛋白B(ApoB)、及脂蛋白a(Lp(a))...